Biotech Stocks and Advisory Committees: No News Is Good News?
By
Michael McCaughan / Email the Author / The RPM Report February 2012, Vol. 8, No. 3
Street Smarts / Word Count: 1249 / Article # 2012500034
Executive Summary
FDA has approved six new molecules already in 2012--and five were approved without going to an advisory committee. Meanwhile, FDA has held four advisory committees to review new drug applications, and all four ended in overwhelming "no" votes.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.